Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane and Xeloda in early operable breast cancer
NCT03647514Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Dec 2018
- Primary completion
- Sep 2020
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
01
Overview
Open-label, single-arm trial of nab-paclitaxel and capecitabine in breast cancer, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Overall Response Rate at 12 weeks. Status: unknown.
02
Drugs
nab-paclitaxelcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03647514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03647514.